drugset / Trial / NCT02215746

Bioavailability of BI 44370 TA Drinking Solution or Tablets With and Without a High Fat Meal in Healthy Male and Female Volunteers

NCT02215746

Phase 1 Completed 12 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of this trial was to evaluate the relative oral bioavailability and pharmacokinetics of BI 44370 TA drinking solution (100 mg and 200 mg) and BI 44370 TA tablets (100 mg as two 50 mg tablets) with and without a high fat meal and to assess the safety and tolerability of the substances.

Timeline

Start
2008-01
Primary completion
2008-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 44370 Small molecule 100 mg Oral
Subject BI 44370 Small molecule 200 mg Oral

Indications

No indication recorded.